SIGA Technologies, Inc. (NASDAQ: SIGA)*
As of March 2025
Financial Performance
Q4 2024 product sales: $80 million
Full-year 2024 product sales: $133 million (up 2% from 2023)
Q4 2024 pretax operating income: $57 million
Full-year 2024 pretax operating income: $70 million
Strong cash position: $155 million with no debt as of December 31, 2024
$70 million in outstanding orders expected to be delivered in 2025
Product Distribution
Q4 deliveries included:
$51 million oral TPOXX and $9 million IV TPOXX to the Strategic National Stockpile (SNS)
$9 million primarily oral TPOXX to the U.S. Department of Defense
$11 million sale to an international customer in East Asia (more than double the largest prior sale in the region)
Full-year 2024 sales mix:
$74 million oral TPOXX to SNS
$26 million IV TPOXX to SNS
$10 million oral and IV TPOXX to Department of Defense
$23 million oral TPOXX to 13 international customers
Key Business Developments
Japan's Pharmaceuticals and Medical Devices Agency approved TPOXX for treatment of orthopoxviruses
SIGA assumed responsibility for promoting TPOXX outside the U.S. from Meridian Medical Technologies
Licensed a portfolio of preclinical monoclonal antibodies from Vanderbilt University for potential treatment of orthopoxviruses
Post-Exposure Prophylaxis (PEP) Program progressing with FDA submission targeted for early 2026
TPOXX Clinical Trials for Mpox
PALM 007 and STOMP trials did not meet primary endpoints for mpox treatment
Results showed potential benefits for patients treated early or with severe disease
Management noted trials enrolled patients at later stages (5.9-8 days after symptom onset)
Emphasized TPOXX's mechanism works best when administered early in infection
Future Outlook
Working with new U.S. administration on a potential new TPOXX contract in 2025
Continuing to build international sales and marketing infrastructure
Anticipate making capital management decisions in Q2 2025 (potential special dividend)
Exploring portfolio diversification opportunities beyond TPOXX